Vertex Pharmaceuticals Inc (VRTX) Return on Investment ROI from the second quarter of 2026 to second quarter of 2025 and for the year 2026, average high and low, overall ranking from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Vertex Pharmaceuticals Inc  (NASDAQ: VRTX)


Vertex Pharmaceuticals Inc's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Vertex Pharmaceuticals Inc's ROI in the second quarter of 2026?
Vertex Pharmaceuticals Inc achieved a return on average invested assets (ROI) of 19.97 % in its second quarter of 2026, this is above VRTX's average return on investment of 9.55%.
Vertex Pharmaceuticals Incs investments during the 12 months ending in the second quarter of 2026 are valued at $22 billion

ROI fell compared to the first quarter of 2026, despite the net income growth of 6.63% from the first quarter of 2026.

Within the Healthcare sector 11 other companies had a higher return on investment. While the total ranking for ROI remained the same, compared to the first quarter of 2026 at no. 320.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Investment Change TTM 15.78 % 16.12 % 9.77 % 5.66 % 2.99 %
Y / Y Net Income Change TTM 21.1 % - - - -
Investment (TTM) in Millions 23,485 22,604 21,782 20,387 19,898
Return On Investment (TTM) 19.97 % 20.49 % 19.48 % 18.76 % 19.09 %
VRTX's Overall Ranking # 320 # 320 # 305 # 349 # 294
Seq. Investment Change TTM 4.24 % 4.32 % 3.59 % 2.78 % 4.54 %
Seq. Net Income Change TTM 1.54 % 9.74 % 7.57 % 1.03 % -
Net Income (TTM) in Millions 4,405 4,338 3,953 3,675 3,638

VRTX Company Profile >> Back to VRTX Roi Comparisons >> See Annual VRTX Return On Investment



Return On Investment VRTX's Ranking
Within: No.
Industry # 4
Sector # 12
Overall # 320

Return On Investment Statistics
High Average Low
52.39 %
9.55 %
-42.41 %
(Dec 31 2018)   (June 30. 2015)







Financial Statements
Vertex Pharmaceuticals Inc's II. Quarter Investments $ 23,485 Millions VRTX's Balance sheet
Vertex Pharmaceuticals Inc's II. Quarter Income $ 1,100 Millions Quarterly VRTX's Income Statement
VRTX's Income by Division See VRTX's Income by Division


VRTX Annual Return On Investment (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Investments in Millions 21,782 18,969 19,183 15,409 11,291
Y / Y Investment Growth 14.83 % -1.12 % 24.49 % 36.48 % 14.34 %
Net Income in Millions 3,953 -536 3,620 3,322 2,342
Y / Y Net Income Growth - - 8.96 % 41.84 % -13.63 %
Annual Return On Investment 18.15 % -2.82 % 18.87 % 21.56 % 20.74 %


Annual Roi Comment
In the fiscal year 2025 ROI improved to 18.15 % compared to the prior year, due to net income growth.

Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
VRTX's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for VRTX's Competitors
Subscribers only: Roi for Vertex Pharmaceuticals Inc's Suppliers
Subscribers only: Return On Investment for VRTX's Customers

Other Ratios
VRTX's Roa VRTX's Inventory Turnover Ratio VRTX's Growth Rates VRTX's Dividend Statistics
VRTX's Profitability Ratios VRTX's Asset Turnover Ratio VRTX's Dividend Growth
VRTX's Roe VRTX's Valuation Ratios VRTX's Financial Strength Ratios VRTX's Dividend Payout Ratio



Companies with similar Return On Investment at Jun 30 2026, within Healthcare Sector ROI
Elite Pharmaceuticals Inc   53.48 %
Idexx Laboratories Inc  51.80 %
Aurinia Pharmaceuticals Inc   50.35 %
Qhslab Inc   48.94 %
Q32 Bio Inc   47.43 %
Vaxart Inc   46.17 %
Liquidia Corporation  42.09 %
Tg Therapeutics Inc   39.26 %
Medpace Holdings Inc   35.54 %
Mettler toledo International Inc   34.41 %
Eli Lilly And Company  33.95 %
Acadia Pharmaceuticals Inc   31.05 %
Caredx Inc   29.42 %
Adma Biologics Inc   28.94 %
Protalix Biotherapeutics inc   25.72 %
Pro dex Inc   24.29 %
Innoviva Inc   23.33 %
Electromed Inc   23.18 %
Zevra Therapeutics Inc   22.90 %
Iradimed Corporation  22.57 %
Alnylam Pharmaceuticals Inc   22.10 %
Eton Pharmaceuticals Inc   21.31 %
Dexcom Inc   20.98 %
Healthcare Services Group Inc   20.93 %
Arcutis Biotherapeutics Inc   20.77 %
Chemed Corporation  20.13 %
Resmed Inc   20.01 %
Halozyme Therapeutics Inc   19.99 %
Vertex Pharmaceuticals Inc  19.97 %
Agilent Technologies inc   19.84 %

Date modified: 2026-09-02T20:09:09+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.